National Vision Holdings Highlights Nordic Pharma's LACRIFILL Gel at AAO for Dry Eye Treatment

Transforming Dry Eye Treatment: Nordic Pharma's LACRIFILL Gel at AAO Annual Meeting

Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., is set to make a significant impact at the American Academy of Ophthalmology (AAO) Annual Meeting in Orlando, FL, from October 18-20, 2025. The company showcases its innovative LACRIFILL Canalicular Gel, a treatment designed specifically for managing symptoms of dry eye—an increasingly prevalent condition affecting millions. The gel is not only groundbreaking in its formulation but also demonstrates promising efficacy, as evidenced by recent patient data indicating that an impressive 98.11% of both first-time and repeat users are willing to return for additional doses. This statistic, shared by Jai Parekh, MD, MBA, Chief Commercial Officer of Eye Care U.S., underscores the product's positive reception among patients seeking relief from dry eye symptoms.

The importance of dry eye management cannot be overstated, particularly in the context of ophthalmic surgeries such as cataract and refractive procedures. Leading ophthalmologists, including Vance Thompson, MD, Kayla Karpuk, OD, and Mark Packer, MD, are collaborating on a "Critical Perspectives" article that addresses the role of lacrimal occlusion in preoperative care. By integrating LACRIFILL into treatment protocols, clinicians can support patients both before and after surgical interventions, ultimately enhancing surgical outcomes. The gel’s ability to provide sustained relief for up to six months positions it as a pivotal option for eye care professionals aiming to address this common ailment effectively.

Nordic Pharma's commitment to advancing the field of ophthalmology extends beyond product innovation. The company proudly sponsors the Women in Ophthalmology (WIO) Awards Ceremony at the AAO, reflecting its dedication to empowering women within the medical community. Attendees at the conference are encouraged to visit booth #1401 for live injection demonstrations of LACRIFILL and to place orders. Additionally, the recent TFOS Dry Eye Workshop III report includes two studies validating the efficacy of the canalicular filler, showing significant improvements in corneal staining and Schirmer test scores when compared to traditional hydrogel canalicular plugs. This research further solidifies LACRIFILL’s role in advancing dry eye management and highlights Nordic Pharma's commitment to education and awareness in the ophthalmology field.

In summary, Nordic Pharma's participation in the AAO Annual Meeting not only promotes an innovative treatment for dry eye but also showcases its broader commitment to supporting women in ophthalmology and enhancing patient care through education and research. The LACRIFILL Canalicular Gel represents a transformative approach to managing a condition that affects many, and its introduction is poised to change how eye care professionals address dry eye symptoms.